Videos

Bhavesh Shah, RPh, BCOP, provides a brief history of PARP inhibitors in the cancer space, as well as his own introduction to PARP inhibitors.

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.

Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), discusses the SHC’s recently released Flu DRIVE Toolkit, which was designed to help overburdened health systems improve flu vaccination rates among vulnerable populations.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, describes some of the challenges providers face during the treatment of patients with advanced cutaneous T cell lymphoma and how to address them.

A panel of experts in the field of ketamine therapy discuss the role of the pharmacist in this field and the future of ketamine and assisted therapies based on current medical research.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.

Andrea Silber, MD, said the COVID-19 pandemic has exacerbated disparities that already existed within oncology care, and she said the effects of these disparities on patients are very real and direct.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.

In part 2 of their discussion on COVID-19 vaccine mandates, experts Ned Milenkovich, PharmD, and Ron Lanton III, Esq., discussed how provider status could impact potential legal issues around COVID-19 vaccine mandates.

Immune globulin subcutaneous (human), 20% solution (Cuvitru) is approved for primary immunodeficiency in patients 2 years of age and older.

Thomas Menighan, co-founder of PursueCare and the CEO Emeritus of the American Pharmacists Association, discusses a pharmacists role in National Recovery Month.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

With the recent announcement of federal COVID-19 vaccine mandates, in addition to private businesses potentially requiring vaccines for employees, pharmacies and other health care facilities could have questions about legal issues surrounding these mandates.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

Sophia Humphreys, PharmD, MHA, said data are continuing to evolve around the safety and recommendations of COVID-19 booster doses, especially for the vaccine from Pfizer and BioNTech.

Gemtesa (vibegron; Urovant Sciences) tablets are approved to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Pharmacy Times spoke with Dr. Bradley Monk, investigator for KEYNOTE-826, #LBA2, which was presented at the ESMO Congress 2021, about the study and its importance to the world of cervical cancer.

Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

Jason Ausili, PharmD, the Chief Clinical Officer of FDS Amplicare, discusses the impact on community pharmacies and patients of the recent announcement by the HHS regarding the amendment to the COVID-19 PREP Act.

Aaron Clark, DO, medical director of value based care at Ohio State University and clinical associate professor of family medicine, discusses vaccine hesitancy and racial disparities around flu vaccinations.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

A panel of experts from various settings in the pharmacy field discuss the application of cultural humility and their own experiences when providing culturally appropriate care to underserved or marginalized populations.

Lola Fashoyin-Aje, MD, MPH, associate director of Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence, discusses the importance of promoting inclusion of members of racial and ethnic minority groups in cancer drug trials.

Dupilumab (Dupixent) was approved in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Unlike other medications for chronic idiopathic constipation, prucalopride works by enhancing colonic peristalsis to increase bowel motility.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses whether the process may be similar in the future in terms of compounding pharmacies’ role in the administration of psychedelic drugs like psilocybin.